Table 1.
Baseline characteristics based on triglycerides levels.
| Variable | High triglycerides level | p value | |
|---|---|---|---|
| Yes (n, %) N = 1,016 (82.3%) |
No (n, %) N = 218 (17.7%) |
||
| Male | 893 (87.9) | 172 (78.9) | <0.001 |
| Female | 123 (12.1) | 46 (21.1) | |
| Age group (year) | |||
| ≤20 | 2 (02.) | 1 (0.5) | 0.003 |
| 21–30 | 44 (4.3) | 10 (4.6) | |
| 31–40 | 187 (18.4) | 34 (15.6) | |
| 41–50 | 301 (29.6) | 43 (19.7) | |
| 51–60 | 269 (26.5) | 59 (27.1) | |
| >60 | 213 (21.0) | 71 (32.6) | |
| Qatari | 72 (7.1) | 35 (16.1) | <0.001 |
| Non-Qatari | 944 (92.6) | 183 (83.9) | |
| Age (year), median (Δ IQR) | 50.0 (18) | 53.0 (20.0) | <0.001 |
| BMI (kg/m2), median (Δ IQR) | 27.8 (6.7) | 27.3 (7.0) | 0.041 |
| Smoking and alcohol status | |||
| Non-smoker | 562 (55.3) | 133 (61.0) | 0.013 |
| Smoker | 47 (4.6) | 16 (7.3) | |
| Ex-smoker | 54 (5.3) | 16 (7.3) | |
| Unknown | 353 (34.7) | 53 (24.3) | |
| Non-alcoholic | 518 (51.0) | 130 (59.6) | 0.019 |
| Alcoholic | 39 (3.8) | 12 (5.5) | |
| Former | 23 (2.3) | 1 (0.5) | |
| Unknown | 436 (42.9) | 75 (34.4) | |
| Comorbidities | |||
| Hypertension | 530 (52.2) | 138 (63.3) | 0.003 |
| Diabetes mellitus | 601 (59.2) | 131 (60.1) | 0.798 |
| CAD | 88 (8.7) | 49 (22.5) | <0.001 |
| PVD | 5 (0.5) | 2 (0.9) | 0.448 |
| History of DVT/PE | 61 (6.0) | 11 (5.0) | 0.584 |
| Heart Failure | 55 (5.4) | 32 (14.7) | <0.001 |
| Atrial fibrillation | 89 (8.8) | 23 (10.6) | 0.404 |
| CKD/ESRD | 143 (14.1) | 32 (14.7) | 0.817 |
| Liver disease | 56 (5.5) | 20 (9.2) | 0.041 |
| COPD | 25 (2.5) | 6 (2.8) | 0.803 |
| ILD | 5 (0.5) | 0 (0.0) | 0.299 |
| PUD | 12 (1.2) | 7 (3.2) | 0.027 |
| Solid tumor | 27 (2.7) | 9 (4.1) | 0.242 |
| Lymphoma | 7 (0.7) | 1 (0.5) | 0.701 |
| Leukemia | 10 (1.0) | 0 (0.0) | 0.141 |
| Organ transplant | 16 (1.6) | 2 (0.9) | 0.463 |
| Dementia | 13 (1.3) | 4 (1.8) | 0.523 |
Chi-square, Fisher Exact’s, and Mann–Whitney tests were used at alpha 0.05. CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; ESRD, end-stage renal disease; ILD, interstitial lung disease; IQR, interquartile range; PE, pulmonary embolism; PUD, peptic ulcer disease; PVD, peripheral vascular disease.